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Abstract
Background: Hepatitis C Virus (HCV) has two envelop proteins E1 and E2 which is highly glycosylated and play an
important role in cell entry. Inhibition of virus at entry step is an important target to find antiviral drugs against
HCV. Glanthus Nivalis Agglutinin (GNA) is a mannose binding lectin which has tendency for specific recognition
and reversible binding to the sugar moieties of a wide variety of glycoproteins of enveloped viruses.
Results: In the present study, HCV pseudoparticles (HCVpp) for genotype 3a were produced to investigate the
ability of GNA to block the HCV entry. The results demonstrated that GNA inhibit the infectivity of HCVpp and HCV
infected serum in a dose-dependent manner and resulted in 50% reduction of virus at 1 ± 2 μg concentration.
Molecular docking of GNA and HCV glycoproteins (E1 and E2) showed that GNA inhibit HCV entry by binding
N-linked glycans.
Conclusion: These results demonstrated that targeting the HCV glycans is a new approach to develop antiviral
drugs against HCV.
Background
HCV is a serious health problem that affects 200 million
people worldwide and 10 million people in Pakistan [1].
HCV causes acute and chronic hepatitis infection which
can eventually lead to permanent liver damage, hepatocel-
lular carcinoma and death [2]. It was estimated by the
World Health Organization in 2004 that the annual deaths
due to liver cancer caused by HCV and cirrhosis were
308,000 and 785,000, respectively [3]. HCV is a blood-
borne pathogen, which transmitted through parenteral
exposure to contaminated blood or body fluids [4]. Factors
most strongly associated with HCV infection are blood
transfusion (56%), alcohol consumption (44%) and intrave-
nous drug abuse (31%) [4,5]. Some other risk factors
include use of inadequately sterilized medical equipment,
high-risk sexual behaviors, and social or cultural practices
such as body piercing, circumcision, and tattooing [6,7].
HCV is a small enveloped virus with a positive-sense,
single-stranded RNA genome that encodes a large poly-
protein of 3010 amino acids (aa). The polyprotein is co-
and post-translationally processed by cellular and virally
encoded proteases to produce four structural (Core, E1,
E2 and P7) and six non-structural proteins (NS2, NS3,
NS4A, NS4B, NS5A, NS5B). HCV envelop proteins E1
and E2 are highly glycosylated and play an important role
in cell entry. E1 serves as the fusogenic subunit and that
E2 acts as the receptor binding subunit of the HCV envel-
ope. The E1 envelope glycoprotein of HCV contains 4 to 5
N-linked glycans and the E2 envelope glycoprotein has 11
N-glycosylation sites [8,9]. However, the number of glyco-
sylation sites varies according to genotype. Glycosylation
sites on E1 and E2 are highly conserved and consists a
combination of complex and high-mannose side-chains.
HCV glycans play an important role in envelope glycopro-
tein folding and formation of the HCV E1E2 complexes,
receptor interactions, virus entry [9] and antigenic varia-
tion [10].
Galanthus nivalis agglutinin (GNA), known as snowdrop
lectin is a mannose-specific, tetrameric protein, consisting
of 4 identical subunits of approximately 12 kDa [11]. GNA
is carbohydrate binding agent which has tendency for spe-
cific recognition and reversible binding to the sugar moi-
eties of a wide variety of glycoproteins. GNA directly
interact with the glycans of the viral glycoprotein of envel-
oped viruses and causes interruption of virus entry (i.e.
fusion) into its target cell [12-14].
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In the current study, HCV entry is blocked by binding
the Glanthus Nivalis Agglutinin with HCV glycosylation
site. For this purpose first of all HCV E1 and E2 envel-
ope proteins of local 3a genotype were docked with
GNA to find out the target site of ligand binding. Then
toxicity of GNA in liver and fibroblast cells was checked
though trypan blue dye and MTT cell proliferation
assay. After the toxicological analysis of GNA, HCV
entry was found to be blocked at non toxic dose.
Materials and methods
Sample Collection
Sera from patients chronically infected with HCV without
any previous history of antiviral treatment were collected
from Molecular Diagnostic Lab, Centre of Excellence in
Molecular Biology (CEMB) under the provision of Institu-
tional Review Board (IRB) of CEMB. The participating
subjects gave informed consent for the collection of blood
samples for this study. The estimated duration of infection
varied from 6 months to 10 years among the patients.
Study included HCV blood from both male and female
patients excluding children. The diagnosis of chronic
HCV was based on elevated serum ALT (SGPT) and AST
(SGOT) levels at least for six months, histological exami-
nation, and consistent detection of serum HCV RNA were
present in each patient. All patients were negative for
HBs Ag.
Cell lines
Huh-7 and HEK 293 T cells were cultured in Dulbecco’s
Modified Eagle medium (DMEM) supplemented with 10%
fetal calf serum, 100 IU/ml penicillin and 100 μg/ml strep-
tomycin, at 37°C in an atmosphere of 5% CO2. CHO cells
were cultured in DMEM Hams F12 supplemented with
5% fetal calf serum, 100 IU/ml penicillin and 100 μg/ml
streptomycin. Huh-7 was kindly provided by Dr. Zafar
Nawaz (Biochemistry and Molecular Biology Department,
University of Miami, USA). CHO was provided by Dr.
Ahmad Usman Zafar (Biopharmaceutical Lab, CEMB,
Pakistan).
Plasmids
The pcDNA-E1E2 expression vector encoding the E1 and
E2 glycoproteins (171-746) of HCV genotype 3a, was gen-
erated by inserting into a nonpackageable, CMV promo-
ter-driven expression construct. (provided by Shazia
Rafique, virology lab, CEMB, Pakistan). The CMV-Gag-
Pol murine leukemia virus (MLV) packaging construct,
encoding the MLV gag and pol genes, and the pTG-Luci-
ferase plasmid provided by Dr. Jaean Dubison, France.
Chemicals
Glanthus Nivalis Agglutinin was purchased from Sigma
Aldrich (Cat. No.L8275 St. Louis, MO, USA. Monoclonal
antibody specific to HCV E2 (Cat. No.sc-57769 was
purchased from Santa Cruiz Biotechnology. Glyceralde-
hydes-3-phosphate dehydrogenase (GAPDH) and sec-
ondary goat anti-mouse monoclonal antibodies were
purchased from Sigma Aldrich (St. Louis, MO, USA).
Molecular docking of GNA with HCV E1 and E2
glycoprotein
Molecular docking is a method which predicts the pre-
ferred orientation of one molecule to a second when
bound to each other to form a stable complex [15].
Docking is frequently used to find out the binding orien-
tation of small molecule drug candidates to their protein
targets in order to in turn predict the affinity and activity
of the small molecule. Hence, docking plays an important
role in drug design [15].
The 3-D structures of GNA lectin were obtained from
Swiss Prot (PDB code: 1JPC, 1NIV) (http://www.rcsb.org/
pdb/home/home.do), (Acc. no: 1JPC, 1NIV). 1JPC struc-
ture is a complex of mannose specific agglutinin (lectin)
from snow drop (Galanthus Nivalis) bulbs with man-
nose-alpha1, 6-(mannose-alpha1, 3)-mannose-alpha1, 6-
(mannose-alpha1, 3)-mannose. 1NIV structure is a com-
plex of mannose specific agglutinin (lectin) from snow
drop (Galanthus Nivalis) bulbs with mannose-alpha1, 3-
methyl-D-mannose. For 3-D structure of HCV protein,
sequence of HCV was taken from EMBL (http://www.ebi.
ac.uk/, Acc. No: ABY83295, M67463). 3-D protein model
of HCV was generated from MUSTER (http://zhang.
bioinformatics.ku.edu/). Vakser server was used for pro-
tein-protein docking (http://vakser.bioinformatics.ku.
edu/). Ten protein-protein complexes were generated for
each 3-D model by protein docking through vakser.
Production of HCVpp and infection
HCVpp were produced by co-transfection of 293-T cells
with equal amounts of three expression vector as
described previously [16]. Supernatants containing pseu-
doparticles were harvested 48 h later, filtered through
0.45 μm pore-sized membranes and stored at -80°C
before use in infection of Huh7 cells.
Cell proliferation assay
MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazo-
lium bromide) is a rapid and sensitive in-vitro procedure
for evaluating cellular toxicity of compounds. The MTT
substance is reduced by mitochondrial succinic dehydro-
genases in living cells to purple formazan crystals that are
not soluble in aqueous water. The absorption of dissolved
formazan in the visible region correlates with the number
of viable cells [17]. To investigate cellular toxicity, 2 × 104
Huh-7 cells were plated into 96-well plates. After 24 h, dif-
ferent concentrations of GNA were added and the plate
was sealed and kept at 37°C in an atmosphere of 5% CO2
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for 24 h. After 24 h, fresh media (100 μl) and MTT solu-
tion (5 mg/ml in PBS) were added to all wells in Columns
1-11. Wrapped the plate in aluminium foil and incubated
for 3-4 h at 37°C. Media was carefully removed and added
100 μl of DMSO to dissolve the formazan crystals in Col-
umns 1-11. MTT formazan product was determined by
measuring absorbance with an enzyme-linked immunosor-
bent assay (ELISA) plate reader at a test wavelength of 570
nm and a reference wavelength of 620 nm.
Cell viability was obtained using the following equation.
Percent cell viability = (Test 570nm− 620nm/Control 570nm− 620nm)× 100
Anti-infectivity of GNA in liver cells
Huh-7 cells were seeded at density of 3 × 105 cells per
35 mm plate. After 24 h, cells were washed twice with
1XPBS. Then, viral inoculations of 105 IU HCV virus of
genotype 3a in each well were performed after washing
twice with 1X PBS. First well was considered as control
(only HCV infected serum and solvent in which GNA
was dissolved) and added dose of GNA (minimum cell
killing) in the remaining five wells on the same day for
checking the antiviral response of compounds. Total
RNA was isolated by using Gentra RNA isolation kit
(Gentra System Pennsylvania, USA) according to the
manufacturer’s instructions. Briefly, cells were lysed with
cell lysis solution containing 5 μl internal control
(Sacace Biotechnologies Caserta, Italy). RNA pallet was
solubilized in 1% DEPC (Diethyl pyrocarbonate treated
water). HCV RNA quantifications were determined by
Real Time PCR Smart Cycler II system (Cepheid Sunny-
vale, USA) using the Sacace HCV quantitative analysis
kit (Sacace Biotechnologies Caserta, Italy) according to
the manufacturer’s instructions.
Formula for the calculation of HCV RNA concentration
Following formula was used to calculate the concentra-
tion HCV RNA of each sample.
Cy3 STD/Res
Fam Std/Res
× coefficient IC = IU HCV/ml
IC = internal control, which is specific for each lot.
Protein isolation and estimation
Cells were harvested after the 24 h of transfection and
protein was isolated for expression analysis. Transfected
cells were washed with 1X PBS. TEN buffer at volume
of 500 μl was added to dislodge the cells and then were
scrapped off after 15 sec. The cells were then pellet
down by centrifugation for 5 min at 13000 rpm at 4°C.
Pellet down cells were then lysed by adding 100 μl of
lysis buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl,
0.02% Sodium azide, 1% Triton X-100, 1 μg/ml protease
inhibitors, and 100 μg/ml PMSF), incubated on ice for
15 min and centrifuged at 13,000 rpm at 4°C for
30 min. Supernatant containing protein was stored at
-20°C. The isolated protein was quantified by spectro-
photometric method. Protein sample (1 μl) was diluted
in 800 μl of 1X PBS and 200 μl of Bio Rad dye and
absorption was taken at 595 nm of wavelength.
Western blotting
Western blotting provides information about presence,
molecular weight, and/or quantity of an antigen by com-
bining protein separation via gel electrophoresis with
specific recognition of antigens by antibodies. To study
protein expression of HCV genes and inhibitory effect
of compounds, 100 μg of total protein was loaded on
10% SDS-PAGE gels and electrophoretically blotted
onto a nitrocellulose membrane (Bio-Rad). The mem-
branes were blocked for 1 h at room temperature with
phosphate-buffered saline containg 5% skim milk and
incubated with HCV specific primary antibody. After
being washed with 1X PBS containing 0.1% Tween 20,
the membranes were treated with monoclonal antibodies
specific to HCV envelop protein E2 and GAPDH (Santa
Cruz Biotechnology). The membrane was then treated
with HRP conjugated anti mouse secondary antibody for
1 h at room temperature. The expression of protein was
evaluated by using chemiluminescence’s detection kit
(Sigma Aldrich).
Statistical Analysis
All statistical analysis was done using SPSS software
(version 16.0, SPSS Inc). Data are presented as mean ±
SD. Numerical data were analyzed using student’s t-test
and ANOVA. P value < 0.05 was considered statistically
significant.
Results
Docking of mannose binding against HCV glycoprotein
Before docking, binding sites for GNA was observed. The
residues involved in binding with mannose in all three 3D
structures of GNA were Gln26, Asp28, Asn30, Tyr34,
Gln57, Asp59, Asn61, Tyr65, Gln89, Asp91, Asn93 and
Tyr97. N-glycosylation sites for HCV protein were also
examined by carrying out pair alignment of sequences of
HCV subtype 3a (Acc. No: ABY83295) with HCV subtype
1a (Acc. No: M67463) (Data not shown). Interactions
among different residues, in each of the ten protein-protein
complexes of both 3-D structures were observed. Among
these the most interesting interactions are the binding of
active site residues of GNA lectin Asn30 and Asn61 with
N glycosylation site of HCV, Asn18. The interaction of
Asn 18 of HCV protein with Asn30 and Asn61 of GNA
lectin was observed in protein-protein complex of 1JPC,
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whereas in 1NIV interaction of only Asn18 with Asn61 was
observed. Figure 1 shows that HCV protein does show
interactions with GNA lectin. Some of the residues show
interaction with binding pockets of GNA lectin. Interac-
tions among the N-glycosylation site of HCV and binding
pocket of GNA lectin was also observed. From these results
it can be concluded that GNA lectin may play role in inhi-
biting HCV activity and hence can be considered for
further studies.
Toxicological study of GNA in liver and fibroblast cells
Cytotoxic effects of GNA were analyzed after 24 h incu-
bation of Huh-7 and CHO cells with different
concentration of GNA. Figure 2 depicts cytotoxicity ana-
lysis of GNA and demonstrates that Huh7 and CHO cell
viability is unaffected by concentrations up to 10 μg.
However, when exceed from 10 μg, toxic effect in liver
and fibroblast cells has been observed. The data verified
by microscopic examination of cells and standard trypan
blue dye measurement, which demonstrate GNA has no
toxic effect at 10 μg concentration.
Anti infectivity of GNA against HCVpp
To determine the effect of GNA on HCV infection,
HCVpp are produced by transfecting the three vectors
in Human embryo kidney cells (293T). The first vector
Figure 1 Docking of GNA lectin with HCV glycoprotein. (a) Interaction of Asn18 of HCV with Asn61 of 1JPC GNA lectin. (b) Interaction of
Asn18 of HCV with Asn30 of 1JPC GNA lectin. (c) Interaction of Asn18 of HCV with Asn61 of 1NIV GNA lectin
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encodes retroviral Gag and Pol, second vector encodes a
reporter protein Luciferase and third vector encodes
HCV glycoproteins E1 and E2. 293T cells secrete virus
pseudo particle an average 105 particle/ml and collect in
media after filtration of 0.45 micron filter. These pseudo
particles can be used to infect Huh-7 cells and infectiv-
ity is evaluated by quantification of amount of luciferase
and through western blotting with HCV E2 specific
monoclonal antibody in the presence and absence of
GNA. Figure 3a and 3b demonstrates that GNA has
antiviral effect against HCVpp in dose-dependent man-
ner. Figure 4 exhibited that GNA showed 50% (EC 50)
reduction of virus at 1 μg concentration. GNA exhibited
90% (EC 90) reduction of virus at 5 μg concentration.
GNA showed antiviral effect by binding to HCV glyco-
protein. These results indicate that GNA possesses anti-
HCV activity at a concentration that does not affect cell
growth.
Discussion
Viral entry is an attractive target to find out antiviral drugs
against HCV. A major advancement to look into HCV
entry process was the development of HCVpp, consisting
of native HCV envelope glycoproteins, E1 and E2,
assembled onto retroviral core particles [8,16,18]. This sys-
tem is potentially very powerful tool to identify and char-
acterize molecules that block HCV entry. In this study,
HCVpp of local HCV genotype 3a were produced to study
early entry steps mediated by HCV envelope glycoproteins.
This assay is based on the quantification of retroviral DNA
Figure 2 Toxicological study of GNA in Huh-7 and CHO cell:
Huh-7 cells were plated at the density of 2 × 104in 96 well plates.
After 24 h cells were treated with different concentrations of GNA
and control consisted of solvent in which GNA dissolved. After 24 h
incubation period add MTT solution to all wells and incubated for
3-4 h at 37°C. Viable cells convert MTT to purple formazan crystal.
Added DMSO to dissolve the formazan crystals and read
absorbance at 570 nm and 620 nm. (a) Toxicological analysis of
GNA in Huh-7 cells through MTT cell proliferation assay. (b)
Toxicological analysis of GNA in CHO cells through MTT cell
proliferation assay.
Figure 3 Antiviral effect of GNA against HCVpp in liver cells.
HCVpp was produced in HEK 293 T cells and collected in media
after filtration in 0.45 micron filter. (a) GNA was incubated with HCV
pseudo particle at 37°C for 1 hr. After 1 hrs Huh-7 cells were
infected with pseudo particle of HCV 3a genotype in the presence
and absence of GNA per well and incubated for additional 48 hrs.
At the end of incubation period protein were isolated and analyzed
by western blotting with anti E2 monoclonal antibody and GAPDH
serve as internal control. (b) GNA was incubated with HCV pseudo
particle at 37°C for 1 h. After 1 h Huh-7 cells were infected with
pseudo particle of HCV 3a genotype in the presence and absence
of different concentrations of GNA and incubated for 3 hrs. After 24
h cells were lysed and luciferase activity was determined by using a
luminometer. Luciferase activity is not reported as an absolute value,
but is calculated relative to the ‘no drug’ condition and reported on
the y-axis as a percentage. Results are represented as the average
and standard error for three independent experiments. P value >
0.05 vs control was considered as statistically significant.
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synthesis, which occurs soon after the fusion of the retro-
viral particle with a cellular membrane. Presumably, this
assay is only dependent on the entry steps mediated by the
heterodimer E1E2 (binding, endocytosis, and fusion) and
on the activity of the reverse transcriptase of the HCVpp
retroviral core. Furthermore, data obtained with HCVpp
was also confirmed with the infection of whole virus of
HCV genotype 3a in liver cells.
HCV E1 envelope glycoprotein contain 4 to 5 N-
linked glycosylation sites and the E2 envelope glycopro-
tein has 11 N-glycosylation sites [8,19,20]. These N-
linked glycosylation sites play an important function in
entry, folding and modulating the immune response.
GNA lectin has been shown antiviral activities against
many enveloped viruses by blocking entry such as HIV
[21,22], Simian immunodeficiency virus (SIV)[23],
HCMV and influenza virus. Our data verified that GNA
inhibit HCVpp and HCV whole genome entry in a
dose-dependent manner and resulted in 50% reduction
of virus at 1 ± 2 μg concentration (Figure 3a and 3b).
HCV serum particles were used as positive control to
study the antiviral effect on real HCV particles (Figure
4). Molecular docking results showed that GNA inhibit
HCV entry by binding to N-linked glycans. However,
due to the absence of a 3D structure for HCV envelope
glycoproteins, it is difficult to identify spatial relation-
ship between HCV glycans and the CD81 binding site.
Contrary to HIV, where mutation in glycosylation sites
resulted in the resistance against GNA [14,24], but the
glycosylation sites in HCV are strongly conserved mini-
mizing the chance of creating resistance against such
drugs targeting glycans [25]. These data clearly con-
firmed that targeting HCV envelope glycans might be a
promising approach in the development of novel anti-
viral therapies.
Development of inhibitors of virus entry, such as
GNA, will reinforce the arsenal against HCV. The cur-
rent treatment of standard interferon in combination
with ribavirin, has limited benefits due to emergence of
resistant mutations during long-term treatment, adverse
side effects and high cost. Consequently, there is a dire
need for the development of more effective, less toxic
antiviral agents. With the passage of time resolution of
the three-dimensional structure of various HCV compo-
nents and the development of in-vitro assays such as
HCVpp and HCVcc to assess the antiviral potency of
molecules targeting these elements have made it possi-
ble to screen and develop specific HCV inhibitors [26].
Currently, the major targets of new antiviral are the
HCV internal ribosome entry site, NS3 serine protease,
and NS5B, the RNA-dependent RNA polymerase.
Although a small number of compounds have started to
show promising results in early-phase clinical trials, pre-
clinical evidence is accumulating, demonstrating that
development of resistance will eventually limit the effi-
cacy of these new drugs [27]. This is due to the fact that
HCV is a highly variable virus with rapid viral kinetics,
large population sizes, and a quasispecies distribution
[27]. Therefore, combinations of multiple drugs with dif-
ferent targets will be required to treat chronic HCV.
Our study demonstrated that GNA inhibit HCV entry
by binding to N-linked glycan at non toxic concentra-
tion. These studies showed that HCV entry process will
help to provide new inhibitors such as GNA and combi-
nation of entry inhibitors with NS3 protease and NS5b
RNA dependent polymerase will provide better option
to treat chronic HCV.
Abbreviations
HCV: Hepatitis C virus; Huh-7: Human Hepatoma Cell line. HCVpp: HCV
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